Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 41 filings·Updated 30 Sept 2026
Showing 10 of 41 filings.
30 Sept 20261 filing
AGM/EGMAGM

Indo Us Bio-Tech's 22nd AGM held via VC/OAVM; resolutions deemed passed subject to final scrutineer report

AGM Details

  • Date and time: 30 Sep 2026, 14:30, via VC/OAVM.

Ordinary resolutions

  • Adopt audited financial statements for year ended 31 Mar 2026.
  • Reappointment by rotation of Priyanka Samarth Patel.
  • Appointment of statutory auditors.

Special resolutions

  • Borrowing limits of the company.
  • Approval of related party transactions under Section 188.

Voting results

  • All resolutions deemed passed on AGM date, pending scrutineer's final report.

Dividend

  • No dividend proposed or declared.

Director changes

  • Priyanka Samarth Patel appointed/reappointed as director (retiring by rotation).

Auditors

  • Statutory auditors appointed (details not disclosed in excerpt).

Material related party transactions

  • Approval of related party transactions under Section 188.
Filed 18:39View Source
28 Sept 20261 filing
Insider Trading / SASTClosure of Trading Window

Indo Us Bio Tech Limited: Trading window closed for Designated Persons from Oct 01, 2026 till completion of 48 hours from the announcement of the unaudited financial results for the quarter and half year ending September 30, 2026.

Indo Us Bio Tech Limited: Trading window closed for Designated Persons from Oct 01, 2026 till completion of 48 hours from the announcement of the unaudited financial results for the quarter and half year ending September 30, 2026.

Filed 10:47View Source
6 Sept 20261 filing
Company UpdateNewspaper Publication

Notice of 22nd AGM of the company to be held 30th September, 2026 through VC/OCAM published in Newspaper.

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 08:55View Source
13 Aug 20261 filing
Company UpdateNewspaper Publication

Submitting Newspaper Advertisement relating to the Unaudited Quarterly Standalone Financial Results for the quarter ended on 30th June, 2026.

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 10:54View Source
12 Aug 20262 filings
ResultFinancial Results

Indo US Bio-Tech approves standalone Q1 FY27 results for quarter ended June 30, 2026; Basic EPS ₹1.51

Financials & approval

  • Board approved standalone unaudited results for quarter ended June 30, 2026; Limited Review Report attached.
  • Basic EPS ₹1.51; Diluted EPS not provided.
  • Auditor's review completed; no material misstatement identified.
  • Board meeting held 12 Aug 2026; timings 14:30–15:10.
Filed 15:34View Source
Board MeetingOutcome of Board Meeting

Indo Us Bio-Tech approves unaudited standalone financial results for quarter ended June 30, 2026

Financial results approved

  • Unaudited standalone financial results for quarter ended 30 June 2026 approved by Board; Audit Committee reviewed.
  • Statement accompanied by limited review report from auditor.
  • Period: quarter ended 30 June 2026; standalone results.
  • Major product segment disclosed as Seed Cultivation, Processing & Trading.
  • Auditor's review indicates no material misstatement; unmodified opinion.
  • Board meeting date: 12 August 2026.
  • Auditor: Bhagat & Associates; Independent Auditor's Review Report under Regulation 33.

Regulatory/compliance notes

  • Statement filed per SEBI LODR Regulation 33; independent limited review conducted.
Filed 15:23View Source
4 Aug 20261 filing
Board Meeting

Indo Us Bio Tech to hold board meeting on 12 Aug 2026 to consider unaudited quarter-ended results

Meeting Details

  • Board meeting scheduled for 12 August 2026; time and venue not disclosed.

Key Agenda Items

  • Unaudited financial results for the quarter ended June 30, 2026 (standalone/consolidated not specified).
  • Other corporate matters.

Other Notes

  • Trading window remains closed 48 hours after dissemination of unaudited standalone results for quarter ended June 30, 2026.
Filed 11:44View Source
21 Jul 20261 filing
Company UpdateStructural Digital Database

COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED ON 30-06-2026

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 16:41View Source
15 Jul 20262 filings
Company UpdateGeneral

Indo Us Bio-Tech announces revised board committee composition effective 21 April 2026

Committee reconstitution

  • Audit Committee reconstituted: Ritaben Kikani (Chair), Shilpa Thumar, Jagdishkumar Ajudiya, Hemanshi Soni (Members).
  • Nomination and Remuneration Committee: Shilpa Thumar (Chair); Ritaben Kikani; Hemanshi Soni (Members).
  • Stakeholders Relationship Committee: Ritaben Kikani (Chair); Jagdishkumar Ajudiya; Hemanshi Soni; Shilpa Thumar (Members).
  • Effective date of reconstitution: 21 April 2026; other disclosures remain unchanged.
Filed 16:24View Source
Company UpdateGeneral

Gautam N Associates resigns; Bhagat & Associates appointed as Indo Us Bio-Tech statutory auditor.

Auditor change

  • Gautam N Associates resigned as statutory auditor effective 15 June 2026.
  • Board approved Bhagat & Associates as statutory auditor on 16 June 2026.
  • Appointment term until the next General Meeting, subject to shareholders' approval.
  • Previous term: Gautam N Associates appointed 30-09-2020; current term through 26th AGM.
  • Reason for change: administrative and operational restructuring of audit assignments.
  • New auditor: Bhagat & Associates, FRN 101100W, Ahmedabad.
  • Old auditor: Gautam N Associates, FRN 103117W.
  • Consent and eligibility confirmed; appointment subject to statutory/regulatory approvals.
Filed 15:54View Source
Showing 10 of 41 filings